Helping Biotron to Do Better and Deliver Tangible Results: Shareholders Call for ASIC Action and Regulatory Scrutiny, page-106

By the way, silence—when combined with delay—gives the people behind BIT and C14 a significant strategic advantage. More often than not, their prolonged silence seems to result in the convenient forgetting of essential business responsibilities, such as timely capital raising or transparent communication with shareholders.

Why is their silence so steep, so deafening, that it causes them to overlook core responsibilities? One possible answer is that the silence is not accidental—it’s intentional. It may be a deliberate tactic to secure undue advantages at the expense of shareholders and public accountability.

Some Undue Advantages Gained Through Silence and Delay:

• Prolonged access to salaries and consulting fees with no requirement to demonstrate commercial outcomes.

• Avoidance of regulatory scrutiny by hiding behind “commercial in confidence” to delay disclosures.

• Insider access to discounted capital raises, allowing related parties to accumulate shares at prices far below previous market value.

• Preservation of board and executive positions without performance-based pressure.

• Control over narrative and timing, selectively releasing information to suit internal agendas rather than market fairness.

• Reduced shareholder resistance, as retail investors grow fatigued, disengaged, or disempowered.